ASMB assemblybio.com: Total Company Value-to-Revenue Ratio

Public company logo of Assembly Biosciences, Inc. (ASMB)

The use of AI platforms for accelerated molecule selection impacts the price-to-sales ratio for Assembly Biosciences (ASMB) on the GURU.Markets chart, where 2185.35 represents the latest metric reading. The financial potential of Assembly Biosciences (ASMB) relies on the development of therapies to eradicate hepatitis B, while operational flexibility is maintained by outsourcing drug synthesis to certified external laboratories.

Assembly Biosciences (ASMB): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/19/2026

ASMB (Assembly Biosciences Inc): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental valuation:ASMB, Assembly Biosciences, Inc.
Flagship merchandise of Assembly Bio

The EV/Sales metric determines the total value of the business, including debt, relative to generated revenue. It identifies asset overvaluation when market expectations outpace actual revenue growth rates. For Assembly Biosciences (ASMB), which relies on grants and partnerships, the EV/Sales chart reflects the speculative value of future drugs. By analyzing this chart, an investor will see the risk of an overheated capitalization before the start of commercial sales. This serves as a critical filter for assessing portfolio sustainability.